期刊
CURRENT NEUROPHARMACOLOGY
卷 20, 期 11, 页码 2019-2023出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X20666220411084612
关键词
Prokyneticin 2; neuroinflammation; Alzheimer's disease; Parkinson's disease; therapeutic targets; clinical biomarkers
资金
- Fondazione Sovena, Rome, Italy
The immune system plays a crucial role in neurodegenerative diseases, and the chemokine PK2 is an important player in these diseases. The potential clinical value of PK2 as a disease biomarker or therapeutic target for Alzheimer's disease and Parkinson's disease is discussed.
The role of the immune system in neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) has become clear in recent decades, as evidenced by the presence of activated microglia and astrocytes and numerous soluble mediators in the brain and peripheral tissues of affected patients. Among inflammatory mediators, chemokines play a central role in neuroinflammation due to their dual function as chemoattractants for immune cells and molecular messengers in crosstalk among CNS-resident cells. The chemokine Bv8/Prokineticin 2 (PK2) has recently emerged as an important player in many age-related and chronic diseases that are either neurodegenerative or systemic. In this perspective paper, we briefly discuss the role that PK2 and its cognate receptors play in AD and PD animal models and in patients. Given the apparent changes in PK2 blood levels in both AD and PD patients, the potential clinical value of PK2 either as a disease biomarker or as a therapeutic target for these disorders is discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据